PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
IOVA vs. MATW
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between IOVA and MATW is 0.16, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.2

Performance

IOVA vs. MATW - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Iovance Biotherapeutics, Inc. (IOVA) and Matthews International Corporation (MATW). The values are adjusted to include any dividend payments, if applicable.

-10.00%0.00%10.00%20.00%30.00%40.00%50.00%JulyAugustSeptemberOctoberNovemberDecember
-11.72%
9.98%
IOVA
MATW

Key characteristics

Sharpe Ratio

IOVA:

-0.06

MATW:

-0.59

Sortino Ratio

IOVA:

0.60

MATW:

-0.72

Omega Ratio

IOVA:

1.07

MATW:

0.92

Calmar Ratio

IOVA:

-0.06

MATW:

-0.37

Martin Ratio

IOVA:

-0.14

MATW:

-0.85

Ulcer Index

IOVA:

38.88%

MATW:

29.41%

Daily Std Dev

IOVA:

87.97%

MATW:

42.38%

Max Drawdown

IOVA:

-99.37%

MATW:

-75.27%

Current Drawdown

IOVA:

-95.31%

MATW:

-56.94%

Fundamentals

Market Cap

IOVA:

$2.39B

MATW:

$904.30M

EPS

IOVA:

-$1.48

MATW:

-$1.93

PEG Ratio

IOVA:

0.00

MATW:

1.92

Total Revenue (TTM)

IOVA:

$90.86M

MATW:

$1.48B

Gross Profit (TTM)

IOVA:

-$12.33M

MATW:

$205.12M

EBITDA (TTM)

IOVA:

-$396.36M

MATW:

$81.86M

Returns By Period

In the year-to-date period, IOVA achieves a -8.24% return, which is significantly higher than MATW's -22.78% return. Over the past 10 years, IOVA has outperformed MATW with an annualized return of -1.11%, while MATW has yielded a comparatively lower -3.68% annualized return.


IOVA

YTD

-8.24%

1M

-12.75%

6M

-8.58%

1Y

-10.55%

5Y*

-24.03%

10Y*

-1.11%

MATW

YTD

-22.78%

1M

-10.51%

6M

9.30%

1Y

-26.45%

5Y*

-3.50%

10Y*

-3.68%

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

IOVA vs. MATW - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Iovance Biotherapeutics, Inc. (IOVA) and Matthews International Corporation (MATW). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for IOVA, currently valued at -0.06, compared to the broader market-4.00-2.000.002.00-0.06-0.59
The chart of Sortino ratio for IOVA, currently valued at 0.60, compared to the broader market-4.00-2.000.002.004.000.60-0.72
The chart of Omega ratio for IOVA, currently valued at 1.07, compared to the broader market0.501.001.502.001.070.92
The chart of Calmar ratio for IOVA, currently valued at -0.06, compared to the broader market0.002.004.006.00-0.06-0.37
The chart of Martin ratio for IOVA, currently valued at -0.14, compared to the broader market-5.000.005.0010.0015.0020.0025.00-0.14-0.85
IOVA
MATW

The current IOVA Sharpe Ratio is -0.06, which is higher than the MATW Sharpe Ratio of -0.59. The chart below compares the historical Sharpe Ratios of IOVA and MATW, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.000.001.002.00JulyAugustSeptemberOctoberNovemberDecember
-0.06
-0.59
IOVA
MATW

Dividends

IOVA vs. MATW - Dividend Comparison

IOVA has not paid dividends to shareholders, while MATW's dividend yield for the trailing twelve months is around 3.54%.


TTM20232022202120202019201820172016201520142013
IOVA
Iovance Biotherapeutics, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
MATW
Matthews International Corporation
3.54%2.54%2.92%2.36%2.87%2.12%1.90%1.33%0.81%1.01%0.95%0.96%

Drawdowns

IOVA vs. MATW - Drawdown Comparison

The maximum IOVA drawdown since its inception was -99.37%, which is greater than MATW's maximum drawdown of -75.27%. Use the drawdown chart below to compare losses from any high point for IOVA and MATW. For additional features, visit the drawdowns tool.


-100.00%-90.00%-80.00%-70.00%-60.00%-50.00%JulyAugustSeptemberOctoberNovemberDecember
-95.31%
-56.94%
IOVA
MATW

Volatility

IOVA vs. MATW - Volatility Comparison

The current volatility for Iovance Biotherapeutics, Inc. (IOVA) is 17.59%, while Matthews International Corporation (MATW) has a volatility of 22.36%. This indicates that IOVA experiences smaller price fluctuations and is considered to be less risky than MATW based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%15.00%20.00%25.00%30.00%JulyAugustSeptemberOctoberNovemberDecember
17.59%
22.36%
IOVA
MATW

Financials

IOVA vs. MATW - Financials Comparison

This section allows you to compare key financial metrics between Iovance Biotherapeutics, Inc. and Matthews International Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2024 PortfoliosLab